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Stage of perinatal development regulates skeletal
muscle mitochondrial biogenesis and myogenic
regulatory factor genes with little impact of growth
restriction or cross-fostering
R. C. Laker1, G. D. Wadley1,2, G. K. McConell1,3 and M. E. Wlodek1*
1Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia
2Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Burwood,
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3Institute of Sport, Exercise and Active Living and the School of Biomedical and Health Sciences, Victoria University, Victoria, Australia
Foetal growth restriction impairs skeletal muscle development and adult muscle mitochondrial biogenesis. We hypothesized that key genes
involved in muscle development and mitochondrial biogenesis would be altered following uteroplacental insufficiency in rat pups, and
improving postnatal nutrition by cross-fostering would ameliorate these deficits. Bilateral uterine vessel ligation (Restricted) or sham (Control)
surgery was performed on day 18 of gestation. Males and females were investigated at day 20 of gestation (E20), 1 (PN1), 7 (PN7) and 35
(PN35) days postnatally. A separate cohort of Control and Restricted pups were cross-fostered onto a different Control or Restricted mother and
examined at PN7. In both sexes, peroxisome proliferator-activated receptor (PPAR)-g coactivator-1a (PGC-1a), cytochrome c oxidase
subunits 3 and 4 (COX III and IV) and myogenic regulatory factor 4 expression increased from late gestation to postnatal life, whereas
mitochondrial transcription factor A, myogenic differentiation 1 (MyoD), myogenin and insulin-like growth factor I (IGF-I) decreased. Foetal
growth restriction increased MyoD mRNA in females at PN7, whereas in males IGF-I mRNA was higher at E20 and PN1. Cross-fostering
Restricted pups onto a Control mother significantly increased COX III mRNA in males and COX IV mRNA in both sexes above controls with
little effect on other genes. Developmental age appears to be a major factor regulating skeletal muscle mitochondrial and developmental genes,
with growth restriction and cross-fostering having only subtle effects. It therefore appears that reductions in adult mitochondrial biogenesis
markers likely develop after weaning.
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Introduction
Being born small for gestational age significantly increases the
risk of developing insulin resistance and type 2 diabetes later in
life.1–4 Skeletal muscle insulin resistance has been associated with
impaired skeletal muscle mitochondrial biogenesis (synthesis of
new mitochondria) and metabolism.5–7 Mitochondria are the
primary controllers of cellular energy metabolism and impair-
ments in skeletal muscle mitochondrial content and function
have been shown in adult rats born small.8,9 Our laboratory has
shown that foetal growth restriction reduces gene and protein
markers of skeletal muscle mitochondrial biogenesis [e.g. per-
oxisome proliferator-activated receptor (PPAR)-g coactivator-1a
(PGC-1a), mitochondrial transcription factor A (Tfam), cyto-
chrome c oxidase subunits 3 and 4 (COX III and IV)] in
6-month-old adult rats, with males more affected than females.8
This potential impairment in skeletal muscle metabolism may
provide an important mechanistic link to skeletal muscle insulin
resistance5–7 associated with being born small.
The developmental time course for the reduction in mar-
kers of skeletal muscle mitochondrial biogenesis following
uteroplacental insufficiency is unclear. One study reported
that the master regulator of mitochondrial biogenesis, PGC-
1a, mRNA was downregulated in the slow twitch soleus
muscle but upregulated in the fast twitch extensor digitorum
longus muscle of small birth weight offspring at 21 days of
age, with males more affected than females.10 It is important
to consider that the control group used in these studies had
their litter size reduced at birth,10,11 previously shown to alter
postnatal growth and impair skeletal muscle markers of
mitochondrial biogenesis at 6 months of age8 and therefore
impacts on the interpretation of these findings. Conse-
quently, the impact of foetal growth restriction on markers of
skeletal muscle mitochondrial biogenesis and the develop-
mental time course in early life remains unclear.
Low birth weight in humans has also been associated with
reduced muscle mass and strength that persists from child-
hood12–15 through to adult life.16–18 Evidence suggests that
*Author for correspondence: Prof M. E. Wlodek, Department of
Physiology, The University of Melbourne, Parkville, Victoria 3010, Australia.
(Email m.wlodek@unimelb.edu.au)
the structural and functional development of muscles and
muscle fibres is altered in babies born small18–23 and this is
likely to play an important role in the programming of adult
disease. Animal studies show that foetal undernutrition is asso-
ciated with reduced postnatal muscle weight and myofibre
density,20,21,24 along with impaired morphological and con-
tractile characteristics22,23 that may persist into adulthood.25 In
the rat, skeletal muscle develops during mid-to-late gestation and
continues to grow some months postnatally.26–28 During gesta-
tion, skeletal muscle development coincides with the expression
of myogenic regulatory factors (MRFs), which are temporally
expressed throughout perinatal development and control an array
of regulatory and structural genes.29–32 Myogenic differentiation
1 (MyoD), myogenin and MRF4 are involved in skeletal muscle
proliferation and differentiation with expression detected from
mid-to-late gestation.27,33–35 In the rat, myogenesis continues for
up to 2 weeks postnatally after which skeletal muscle hyper-
trophy persists. Insulin-like growth factor I (IGF-I) plays a well-
defined role in skeletal muscle hypertrophy,36–38 but evidence
also implicates IGF-I in skeletal muscle proliferation and dif-
ferentiation.39 Owing to the temporal pattern of MRF expres-
sion, the timing of an insult may be an important determinant of
the muscle’s phenotypic profile. An insult, during gestation or
after birth, may alter the expression of these myogenic regulatory
and growth factors and may impact on later skeletal muscle mass
and function.
Our laboratory has shown that uteroplacental insufficiency
in pregnant rats not only impairs the growth of the foetus but
also impairs maternal mammary development resulting in
poor lactation,40 further compromising the growth of the
offspring after birth.41 In low birth weight humans, improved
growth between birth and 2 years has been shown to reduce the
risk of developing adult metabolic disease.4,42–44 Indeed, Siebel
et al. have shown that improved postnatal nutrition by cross-
fostering growth-restricted pups onto a control mother with
normal lactation, improved early postnatal growth and amelio-
rated the impaired glucose tolerance45 and pancreatic b-cell
mass46 observed at 6 months of age. Furthermore, at 7 days of
age, restricted pups fostered onto a control mother showed
upregulation of key pancreatic genes important for b-cell growth
and maintenance.46 These results highlight the potential for early
life interventions that may lessen the adverse consequences of
being born small.
Therefore, Study 1 determined the impact of uteroplacental
insufficiency on gene expression of skeletal muscle markers of
mitochondrial biogenesis and myogenic regulatory and growth
factors in late gestation and during postnatal life. Study 2
determined whether improved lactation after birth by cross-
fostering could ameliorate any adverse consequences of uter-
oplacental insufficiency on skeletal muscle gene expression in
early life. Finally, due to multiple and significant gender differ-
ences in metabolic disease outcomes in response to impaired
foetal growth reported previously by ourselves8,45 and others,47–49
we determined the impact of uteroplacental insufficiency and
cross-fostering in males and females separately. On the basis of
our and others findings in adulthood, we hypothesized that key
genes involved in skeletal muscle development and mitochondrial
biogenesis would be altered following intrauterine growth
restriction in rats, with different developmental profiles between
males and females.
Methods
Animals
All procedures were approved by The University of Melbourne
Animal Experimentation Sub-Committee. In both studies,
Wistar Kyoto rats (aged 11 weeks) were obtained from the
Australian Resource Centre (Murdoch, WA, Australia) and
house with a 12-h light dark cycle with access to water and
normal chow ad libitum. On day 18 of gestation (term 22 days),
pregnant rats were anesthetized by intraperitoneal injection
of ketamine (225mg/kg) and Ilium Xylazil-20 (30mg/kg).
Bilateral uterine vessel ligation of both the artery and vein
supplying each uterine horn was performed to induce late
gestation uteroplacental insufficiency (Restricted) or sham
surgery was performed to generate the Control group.50,51
Study 1: developmental timeline study
At day 20 of gestation (E20), mothers that underwent either
bilateral uterine vessel ligation or sham surgery were anes-
thetized by intraperitoneal injection of ketamine (225mg/kg)
and Ilium Xylazil-20 (30mg/kg) and the uterus exposed. In
Restricted litters at E20, the ligation integrity was confirmed.
Foetuses at E20 or pups at postnatal day 1 (PN1) and 7 (PN7)
were weighed, killed by decapitation and hindlimb skeletal
muscle rapidly excised, pooled within litters and separated by sex
(n5 8–10 litters/group). Skeletal muscle was not weighed at
ages E20, PN1 or PN7 due to potential inaccuracies in dissec-
tion of the muscle in the small animals. Because of the increased
body mass at postnatal day 35 (PN35) individual male and
female offspring were anesthetized by intraperitoneal injection of
ketamine (225mg/kg) and Ilium Xylazil-20 (30mg/kg) and the
gastrocnemius muscle rapidly excised and weighed (n58–10
offspring/group). The gastrocnemius muscle was examined at
PN35 as it is the largest muscle of the lower hindlimb and is also
a mixed fibre muscle making it an appropriate hindlimb muscle
for comparing to mixed hindlimb muscle collected at earlier
ages. All samples collected were immediately frozen in liquid
nitrogen and stored at 2808C.
Study 2: cross-fostering study
In a separate cohort of offspring exposed to uteroplacental
insufficiency or sham surgery, Restricted or Control pups were
cross-fostered 1 day after birth onto either a mother who had
undergone bilateral uterine vessel ligation or a sham-operated
Control mother to yield four treatment groups. Control pups
fostered onto a Control mother (Cont-on-Cont), Control pups
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on Restricted mother (Cont-on-Rest), Restricted pups on Control
mother (Rest-on-Cont) and Restricted pups on Restricted mother
(Rest-on-Rest).46 To determine the early effects of foetal growth
restriction and cross-fostering before the majority of proliferation
and differentiation was complete, hindlimb skeletal muscle was
collected at PN7 as described above (n5 7–10 litters/group).
Analysis for studies 1 and 2: real-time polymerase
chain reaction (PCR) analysis
For the Developmental Timeline Study, total RNA was extracted
from skeletal muscle using the Tri-Reagent (Ambion Inc.,
Austin, TX, USA) method due to the small amounts of pooled
tissue obtained from pups at E20 and PN1. RNA was extracted
from skeletal muscle of the Cross-foster Study using the Invitro-
gen micro–to-midi RNA extraction kits (Invitrogen, Carlsbad,
CA, USA). RNA yield was measured using the NanoDropTM
1000 Spectrophotometer (NanoDrop Technologies, Wilming-
ton, DE, USA) at 260nm absorbance. Integrity was confirmed
from the 260/280nm ratio and random samples were also
selected for gel electrophoresis with high levels of 18S and 28S
detected.
First-strand cDNA was synthesized from 1mg of RNA
using superscript III first-strand system (Invitrogen). Primer
and TaqmanR probe sequences for PGC-1a, Tfam, COX
III, COX IV, myogenin, MyoD, MRF4, IGF-I, b-actin and
18S are presented in Table 1. Depending on probe availability,
real-time PCR using either SYBR green8 or TaqManR 52
chemistry was performed, as described previously, using the
sequence detector software (Rotor-gene v6, Corbett Research,
Sydney, NSW, Australia). Samples from each age within an
experimental group were amplified on the same run to eliminate
inter-assay variability, whereas a positive control sample was used
as a reference to make inter-assay comparisons within an age
group. In cases when SYBR green chemistry (Tfam, COX III
and COX IV) was utilized, samples were subjected to a heat
dissociation protocol following the final amplification cycle to
ensure that only a single product was detected. Relative gene
expression was quantified using the comparative Ct (DDCt)
method.8,46 18S was used as the endogenous control for the
Developmental Timeline Study (Study 1) as it was stably
expressed across age groups, whereas b-actin was used for the
Cross-foster Study (Study 2) due to stable expression between
treatment groups at that age.
Studies 1 and 2: statistical analysis
At each age, body weight and dimensions were analysed by a
two-way ANOVA for sex and treatment. For the Develop-
mental Timeline Study, gene expression data were analysed
separately for sex using a two-way ANOVA for age and
treatment. If a statistically significant interaction was
observed, data were then split and analysed by one-way
ANOVA with Duncan’s post hoc test where appropriate. For
the Cross-foster Study, gene expression data were analysed T
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Growth restriction and muscle development 41
separately for sex using a one-way ANOVA for treatment.
All data are presented as the mean6 S.E.M. The level of
significance was set at P, 0.05.
Results
Study 1: developmental timeline study
Body weight, dimensions and litter size
Litter size was reduced by uteroplacental insufficiency during
gestation at E20 (8.16 0.7 v. 10.56 0.9; P5 0.05) and after
birth at PN1 (5.26 0.6 v. 8.26 0.5; P, 0.05). Restricted
offspring were lighter (P, 0.05) with shorter crown-rump
length (P, 0.05) than Control at all ages in males and at E20,
PN1 and PN7 in females (Table 2). Hindlimb length was
shorter in Restricted males at E20 and in both sexes at PN7
(Table 2). Head length was shorter in Restricted at PN1 and
head width was shorted in Restricted at PN7 compared with
Controls in both sexes (Table 2). Foetal growth restriction
reduced PN35 absolute gastrocnemius weight in males
(0.266 0.01 g v. 0.206 0.01 g; P, 0.05), but not in females
(0.206 0.02 g v. 0.216 0.02 g). Relative (to body weight)
gastrocnemius weight was unaffected by foetal growth restric-
tion in both males (0.346 0.02 g v. 0.326 0.01 g) and females
(0.316 0.02 g v. 0.326 0.03 g).
Skeletal muscle gene expression
Skeletal muscle mitochondrial biogenesis markers
Uteroplacental insufficiency had no impact on skeletal muscle
gene expression of mitochondrial biogenesis markers regard-
less of sex (Fig. 1). In both males and females, PGC-1a
mRNA was lowest at E20 (P, 0.05) and showed increasing
(P, 0.05) expression such that by PN35 was more than
four-fold higher (P, 0.05) than E20 (Fig. 1a and 1e). In
females, Tfam mRNA was similar between E20 and PN1 and
peaked (P, 0.05) at PN7 (Fig. 1f). In males, Tfam mRNA
was similar at E20, PN1 and PN7 and decreased (P, 0.05)
only at PN35 (Fig. 1b). COX III mRNA levels were similar at
E20, PN1 and PN7 and increased (P, 0.05) substantially by
PN35 in both males and females (Fig. 1c and 1g). Finally,
COX IV mRNA in males and females was similar at E20 and
PN1 and progressively increased such that it was highest
(P, 0.05) at PN35 (Fig. 1d and 1h).
Myogenic regulatory and growth factors
In both males and females, MyoD and myogenin mRNA pro-
gressively decreased such that it was highest at E20 (P,0.05)
and lowest (P,0.05) at PN35 (Fig. 2a, 2b, 2e and 2f, respec-
tively). Uteroplacental insufficiency had no impact on MyoD
and myogenin mRNA in either sex (Fig. 2a, 2e, 2b and 2f,
respectively) except in females at PN7, MyoD mRNA was
, 40% higher (Fig. 2e; P,0.05). MRF4 mRNA was lowest
(P,0.05) at E20 and progressively increased (P,0.05) to T
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peaked (P, 0.05) at PN7 in both sexes (Fig. 2c and 2g).
In males and females, IGF-I mRNA was highest (P,0.05) at
E20 and PN1 and progressively decreased such that expression
was lowest (P,0.05) at PN35 (Fig. 2d and 2h). Uteroplacental
insufficiency increased IGF-I mRNA by approximately 50%
(P,0.05) at E20 and PN1 in male offspring only (Fig. 2d).
Study 2: cross-foster study
Weights and dimensions
The effect of uteroplacental insufficiency and cross-fostering
on body weight and dimensions in the male cohort has pre-
viously been published.46 Briefly, uteroplacental insufficiency
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Fig. 1. Effect of uteroplacental insufficiency on skeletal muscle markers of mitochondrial biogenesis. Hindlimb skeletal muscle peroxisome
proliferator-activated receptor (PPAR)-g coactivator-1a (PGC-1a), mitochondrial transcription factor A (Tfam), cytochrome c oxidase
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reduced litter size compared with sham-operated Controls
(5.66 0.5 v. 8.26 0.7; P, 0.05). Both male (3.426 0.05 g
v. 4.126 0.06 g) and female (3.426 0.07 g v. 4.046 0.07 g)
Restricted offspring were smaller (P, 0.05) than Control at
PN1 and remained smaller (P, 0.05) at PN7 regardless of
cross-fostering (Table 3). At PN7, female restricted pups
fostered onto a control (Rest-on-Cont) mother showed inter-
mediate head length. Male Rest-on-Cont showed improved
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growth displaying increased (P, 0.05) hindlimb length and
head width compared with Rest-on-Rest and intermediate
head length between Cont-on-Cont and Rest-on-Rest (Table 3).
Skeletal muscle gene expression
Skeletal muscle mitochondrial biogenesis markers
PGC-1a mRNA was similar for all groups regardless of the
postnatal environment (Fig. 3a and 3d). Female Rest-on-Rest
pups showed higher (P, 0.05) Tfam mRNA compared with
Cont-on-Cont offspring (Fig. 3e) and there was no impact
of cross-fostering. Interestingly, even though COX III and
IV mRNA levels were similar between Cont-on-Cont and
Rest-on-Rest offspring (Fig. 3), when restricted pups were fostered
onto a control (Rest-on-Cont) mother with normal lactation,
COX III increased (P, 0.05) by up to 50% in males (Fig. 3c),
whereas COX IV mRNA increased (P, 0.05) by up to 50%
above Cont-on-Cont levels in both sexes (Fig. 3d and 3h).
Myogenic regulatory and growth factors
In general, there were few effects of foetal growth restriction or
cross-fostering on MyoD, myogenin and MRF4 mRNA in males
and females (Fig. 4a–4c and 4e–4g, respectively). In females,
myogenin was higher (P,0.05) in Rest-on-Rest and Rest-on-Cont
compared with Cont-on-Rest that were subjected to a suboptimal
postnatal nutritional environment (Fig. 4f). Consistent with data
from Study 1, female Rest-on-Rest MyoD expression was higher
(P,0.05) compared with Cont-on-Cont offspring (Fig. 4e).
There was no impact of foetal growth restriction on IGF-I
(Fig. 4d and 4h); however, IGF-I was altered in a sex-specific
manner upon exposure to a mismatched pre- and postnatal
environment. In females, fostering control pups onto a restricted
mother (Cont-on-Rest) with impaired lactation lowered (P,0.05)
IGF-I mRNA compared with Rest-on-Rest females (Fig. 4h).
Whereas in males, restricted pups fostered onto a control mother
(Rest-on-Cont) with normal lactation increased (P,0.05) IGF-I
mRNA compared with Cont-on-Cont males (Fig. 4d).
Discussion
These studies have shown that skeletal muscle gene expression of
mitochondrial biogenesis markers and myogenic regulatory and
growth factors display age-dependent expression patterns
throughout development. Surprisingly, there was a remarkably
small effect of growth restriction and cross-fostering. However,
foetal growth restriction did trigger a compensatory upregulation
of specific myogenic regulatory and growth factor genes in both
males and females. Improved postnatal lactation in restricted
offspring (Rest-on-Cont) upregulated the mRNA expression of the
mitochondrial proteins COX III and IV above levels observed in
Cont-on-Cont pups. Furthermore, altered postnatal nutrition,
particularly when it was mismatched with the prenatal environ-
ment, caused sex-specific alterations in IGF-I expression, which
were in parallel with sex-specific changes in body weight and
dimensions. These data suggest that skeletal muscle is susceptible
to nutritional intervention during early postnatal life; however, the
functional consequences later in life may not become apparent.
Skeletal muscle gene expression during pre- and
postnatal life (Study 1)
A novel finding of this study was that gene expression of the
master regulator of mitochondrial biogenesis, PGC-1a, and
Table 3. Effect of uteroplacental insufficiency and cross-fostering on body weight and dimensions in male and female rats at PN7
Pup-on-mother Cont-on-Cont Cont-on-Rest Rest-on-Cont Rest-on-Rest
Males
Body weight (g) 10.536 0.66 9.346 0.19 7.476 0.34* 6.616 0.39*
Crown rump (mm) 46.626 0.99 45.216 0.59 41.996 0.62* 40.336 0.97*
Hindlimb length (mm) 14.606 0.24 14.196 0.11 13.226 0.21** 12.506 0.26**
Head length (mm) 16.556 0.23 16.716 0.33 15.736 0.48* 15.186 0.31*
Head width (mm) 12.576 0.20 12.376 0.11 11.746 0.34** 11.066 0.18**
Females
Body weight (g) 9.786 0.21 8.886 0.21** 7.416 0.38# 6.996 0.42#
Crown rump (mm) 46.576 0.65 44.326 0.59** 41.506 1.08# 41.006 0.72#
Hindlimb length (mm) 14.636 0.20 13.936 0.17 13.126 0.36* 12.876 0.29*
Head length (mm) 16.526 0.16 16.696 0.29 15.826 0.46 15.256 0.38*
Head width (mm) 12.666 0.16 12.316 0.13 11.896 0.24* 11.476 0.27*
PN7; postnatal day 7; Cont, Control; Rest, Restricted.
*Denotes significantly (P, 0.05) different form Cont-on-Cont.
#Denotes significantly (P, 0.05) different from Cont-on-Cont and Cont-on-Rest.
**Denotes significantly (P, 0.05) different form all other groups.
Body weight, crown-rump length, hindlimb length, head length and head width measured for male and female offspring. Data are expressed
as mean6 S.E.M. (n5 7–10/group).
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the mitochondrial electron transfer chain proteins, COX III
and IV, increased in skeletal muscle from late gestation and
throughout early postnatal life indicative of increasing mito-
chondrial biogenesis after birth and into the juvenile period.
These data are consistent with previous studies that have
shown in both rats and humans that skeletal muscle oxidative
enzyme activity and mitochondrial DNA (mtDNA) content
is up to 50% higher in adulthood compared with early
postnatal life.53–55 Interestingly, the gene expression profile
of Tfam, the transcription factor responsible for mtDNA
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Fig. 3. Effect of uteroplacental insufficiency and cross-fostering on skeletal muscle markers of mitochondrial biogenesis. Hindlimb skeletal
muscle peroxisome proliferator-activated receptor (PPAR)-g coactivator-1a (PGC-1a), mitochondrial transcription factor A (Tfam),
cytochrome c oxidase subunits 3 and 4 (COX III and IV) mRNA relative to b-actin in male (a–d, respectively) and female (e–h, respectively)
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experimental groups (pup-on-mother): Cont-on-Cont, Cont-on-Rest, Rest-on-Cont and Rest-on-Rest. Values are mean6 S.E.M. (n5 7–10/group).
*Denotes significantly (P, 0.05) different from Cont-on-Cont. **Denotes significantly (P, 0.05) different from all other groups.
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replication, is not reflective of the PGC-1a and COX IV
expression profiles. It is possible that Tfam’s additional role in
maintenance of mtDNA,56 and not just mtDNA replication,
may account for its unique expression profile during skeletal
muscle development.
Consistent with the literature,27,29–39 the timing of myo-
genic regulatory and growth factor expression seems to reflect
their proposed individual roles in skeletal muscle develop-
ment. Indeed, the high levels of MyoD and myogenin during
late gestation and early postnatal life suggest roles in proliferation
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and differentiation,31,57–59 whereas the expression of MRF4,
which peaks around PN7, is consistent with a role in primary
and secondary fibre formation.27,29 Finally, the higher expres-
sion of IGF-I from gestation to at least PN7 may reflect its role
in early skeletal muscle development and growth,39 which is
then downregulated by the early juvenile period when skeletal
muscle differentiation is complete.
It is important to consider that although in the human the
majority of skeletal muscle growth and differentiation occurs in
the last 3 months of gestation, compared with the newborn rat,
human skeletal muscle development is more advanced at birth.
However, skeletal muscle differentiation in the human does
continue after birth with up to 20% of fibres undifferentiated in
the newborn, which drops to adult levels by 1 year of age.53
The impact of uteroplacental insufficiency (Study 1)
Following uteroplacental insufficiency and growth restriction,
skeletal muscle markers of mitochondrial biogenesis were
largely intact during late gestation and postnatal life. It was
particularly surprising to find that foetal growth restriction
had no impact on PGC-1a gene expression as uteroplacental
insufficiency causes foetal hypoxia and in skeletal muscle the
hypoxia inducible factor 1 activity and expression is tightly
coupled to PGC-1a.60 It therefore appears that the deficit
in skeletal muscle markers of mitochondrial biogenesis
previously reported in small birth weight males at 6 months
of age8 likely develop after weaning, during juvenile or early
adult life. Consequently, the impact of foetal growth restriction
on skeletal muscle mitochondrial biogenesis and its time course
in the perinatal period remains unclear.
Specific myogenic regulatory and growth factors showed a
compensatory upregulation following uteroplacental insuffi-
ciency in an age- and sex-specific manner. Female Restricted
offspring showed a significant increase in MyoD gene
expression at PN7. MyoD’s proposed role in skeletal muscle
specification and proliferation suggest that the elevated
mRNA levels observed in Restricted females at PN7 may
represent a delayed myogenic process. Indeed, previous stu-
dies found that offspring of malnourished mothers had
delayed differentiation of muscle fibres at day 7 and to a lesser
extent at day 14 after birth;23 however, this was only inves-
tigated in male offspring. The current study reports that male
Restricted offspring showed an upregulation of IGF-I gene
expression at E20 and PN1. Other studies have found that
following foetal growth restriction in sheep, skeletal muscle
IGF-I levels were either unchanged61 or reduced.62 Impor-
tantly, these studies imposed foetal growth restriction on
pregnant ewes for 6061 and 12162 days of gestation, whereas
we report changes in IGF-I as little as 2 days following the
induction of growth restriction. Indeed, more recently
Costello et al.24 reported that following late gestation under-
nutrition in sheep, reduced myofibre density was associated
with a compensatory upregulation of the IGF-I receptor at
127 days gestation (term 147 days). The upregulation of
IGF-I mRNA reported in the current study may be a
mechanism to drive skeletal muscle growth and hypertrophy
to compensate for potential reductions in fibre number as a
consequence of the suboptimal uterine environment.
The effects of cross-fostering and altered postnatal
lactation (Study 2)
Cross-fostering growth-restricted pups onto a mother with
normal lactation and consequently improved postnatal
nutrition has been shown to increase milk intake63 and, in the
current study, was associated with improved postnatal growth
in males only, indicated by improved head width and hin-
dlimb length.46 It is possible that males are more responsive
to intervention due to their apparently more severe growth
restriction, observed at all ages investigated, and increased
adult disease susceptibility.8,45,47–49,64
Despite foetal growth restriction (Rest-on-Rest) having little
impact on markers of mitochondrial biogenesis, cross-fostering
growth-restricted pups onto a mother with normal lactation
(Rest-on-Cont) was associated with an upregulation of skeletal
muscle COX III mRNA in males only and COX IV mRNA
in males and females above that of Cont-on-Cont levels. COX
III is a mitochondrial-encoded protein, whereas COX IV is a
nuclear-encoded protein, both involved in the electron
transfer chain on the inner mitochondrial membrane and,
therefore, the upregulation of COX III and IV mRNA may
contribute to increased electron transfer chain components to
improve mitochondrial respiration. This upregulation may be
a compensatory response following uteroplacental insufficiency
in the face of improved substrate availability due to improved
postnatal nutrition. How this will impact on the adult skeletal
muscle metabolic profile is unknown, but as cross-fostering has
been associated with improved glucose tolerance in adulthood
of small birth weight rats,45 the gene changes in skeletal muscle
may also contribute to improved adult health.
Finally, female control offspring fostered onto a restricted
mother (Cont-on-Rest) with impaired lactation displayed sig-
nificantly reduced skeletal muscle IGF-I mRNA compared
with Rest-on-Rest offspring. This observation was in parallel
with slowed growth in Cont-on-Rest females displaying lower
body weight and crown-rump length compared with Cont-on-
Cont. In contrast, male restricted offspring fostered onto a
control mother (Rest-on-Cont) and therefore subjected to
improved nutrition after birth, displayed significantly
elevated IGF-I mRNA levels compared with Cont-on-Cont
offspring, along with improved growth indicated by larger
hindlimb length and head width compared with Rest-on-Rest
males. Although foetal growth restriction alone had no
impact in IGF-I mRNA, it appears that expression is altered
in both males and females when the pre- and postnatal
nutritional environments were mismatched and was asso-
ciated with specific changes in body weight and dimensions.
Furthermore, it is possible that the IGF-I gene may be subject
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to a predictive adaptive response to nutritional status during
gestation, which is altered in the face of mismatched postnatal
nutrition. Along with the COX III and IV data, we suggest
that skeletal muscle may be susceptible to specific interventions
in early life. Whether these relatively minor gene changes fol-
lowing cross-fostering will contribute to later disease prevention,
observed at 6 months of age,45,46,51 is unclear; but perhaps an
intervention that occurs at an age when deficits in skeletal
muscle mitochondrial biogenesis markers are present would
provide greater benefits to improved skeletal muscle mito-
chondrial biogenesis and insulin sensitivity.
These unique studies have shown novel developmental
patterns of key genes involved in skeletal muscle mitochon-
drial biogenesis and development in early life. It is important
to acknowledge that mRNA data are limited in its inter-
pretation without accompanying protein, histological or
functional analysis. Because of limitations in the amount of
muscle tissue available, this analysis was not possible in the
current study. Future studies should attempt to confirm the
current gene data with protein analysis as well as histological
analysis to determine whether the increased MyoD and IGF-I
following uteroplacental insufficiency in our rat model is
associated with impaired muscle fibre development, dis-
tribution and number.
Summary
The current studies have shown that skeletal muscle markers
of mitochondrial biogenesis remain intact in early life fol-
lowing foetal growth restriction despite our previous data
showing marked impairments at 6 months of age in males.8 It
is therefore likely that the deficits in mitochondrial biogenesis
develop later in life. Indeed, the upregulation of MyoD and
IGF-I following foetal growth restriction may be indicative
of delayed myogenesis in a sex-specific manner. Improved
postnatal nutrition by cross-fostering improved growth in
males early in life and was associated with upregulation of the
electron transfer chain proteins, COX III and IV in small
birth weight males and females. Whether these subtle changes
will have consequences for later disease outcomes in adult-
hood are unknown.
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